Stephen Hoge - 27 Dec 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
27 Dec 2023
Net transactions value
-$4,500,450
Form type
4
Filing time
28 Dec 2023, 08:00:32 UTC
Previous filing
05 Dec 2023
Next filing
17 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale $4,500,450 -45,000 -2.9% $100.01 1,531,063 27 Dec 2023 Direct F1, F2
holding MRNA Common Stock 4,116 27 Dec 2023 By Valhalla, LLC
holding MRNA Common Stock 151,933 27 Dec 2023 By Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.00 to $100.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.